Healthcare / Medical DevicesTaipei Exchange
$17.10
-0.30 (-1.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-133.9M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-26.7%
↓Gross Margin
-26.6%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-18.7%
FCF CAGR
—
FCF margin
-1324.6%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.5M · net income $-148.5M · FCF $-138.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.5M | $10.5M | $27.5M | $22.5M | $19.5M |
| Net Income | $-148.5M | $-148.5M | $-95.1M | $-65.7M | $-63.6M |
| EBITDA | $-123.1M | $-123.1M | $-77.0M | $-55.8M | $-53.8M |
| EPS | — | — | -1.56 | -1.17 | -1.12 |
| Gross Margin | -26.6% | -26.6% | 35.2% | 52.6% | 84.5% |
| Operating Margin | -1523.4% | -1523.4% | -402.8% | -340.0% | -373.3% |
| Net Margin | -1416.2% | -1416.2% | -345.5% | -292.4% | -325.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.06 | 0.08 | 0.00 |
| Cash Flow | |||||
| Free Cash Flow | $-138.9M | $-138.9M | $-133.9M | $-88.1M | $-81.6M |
| Returns | |||||
| ROE | -26.7% | -26.7% | -19.8% | -15.5% | -13.1% |
| Valuation | |||||
| P/B | 2.18 | 2.18 | 3.55 | 3.69 | 2.80 |
| Growth & Yield | |||||
| Revenue Growth | -61.9% | -61.9% | 22.5% | 15.1% | — |
| EPS Growth | — | — | -33.3% | -4.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.56 → n/d
Residual
-29.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.